Skip to main content
SpringerLink
Log in

Update of the Latest Intervention Trials in Hypertension and Type 2 Diabetes

  • Chapter
The Kidney and Hypertension in Diabetes Mellitus

  • 240 Accesses

Abstract

Patients with hypertension and type 2 diabetes mellitus constitute an important risk group. Their risk of cardiovascular morbidity and mortality is considerably higher than in non-diabetic patients with hypertension [1]. The concomitant appearance of arterial hypertension and type 2 diabetes has appropriately been referred to, by Mogensen, as “double jeopardy” [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes care 1993; 16: 434–444.

    Article  PubMed  CAS  Google Scholar 

  2. Mogensen C E. Editorial: Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ 1998; 317: 693–694

    Article  PubMed  CAS  Google Scholar 

  3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Eimfeldt D, Ménard J, Julius S, Rahn KH, Wedel H, Westerling S for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762.

    CAS  Google Scholar 

  4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.

    Article  Google Scholar 

  5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713–720.

    Article  Google Scholar 

  6. Hansson L, Lindholm L H, Niskanen L, Lanke J, Hedner T, Nikiason A, Luomanmdki K, Dahlöf B, de Faire U, Mérlin C, Kariberg BE, Wester P O, Björck J-E for the Captopril Prevention Project (CAPPP) Study Group. Effect of angiotensin-converting-enzyme Inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  7. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. NEJM 1998;338:645–652. 15

    Article  PubMed  CAS  Google Scholar 

  8. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597–603.

    Article  PubMed  CAS  Google Scholar 

  9. Tuomilehto J, Rastenyte D, Birkenhdger WH, Thijs L, Antikainen R, Buipitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R for the Systolic Hypertension in Europe Trial Investiagtors. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engi J Med 1999:340:677–684.

    Article  CAS  Google Scholar 

  10. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherston B, Wester P-O, Hedner T, de Faire U, for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751–1756.

    Article  PubMed  CAS  Google Scholar 

  11. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high risk patients. NEJM 2000; (to be published January 20, 2000).

    Google Scholar 

  12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413–2446.

    Article  Google Scholar 

  13. Guidelines Sub-Committee. 1999 World Health Organization — International Society of Hypertension guidelines for the management of hypertension. BLOOD PRESSURE 1999;8(suppi 1):1–36.

    Google Scholar 

  14. The HOT Study Group. The Hypertension Optimal Treatment (HOT) Study — A prospective study of the optimal therapeutic goal and the value of low-dose aspirin in antihypertensive treatment. BLOOD PRESSURE 1993;2:113–119. 16

    Article  Google Scholar 

  15. Collins R, Peto R, MacMahon S, Hebert P, Fiebach N H, Eberiein K A, Godwin J, Qizilbash N, Taylor J O, Hennekens C H. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: over-view of randomised drug trials in their epidemiological context. Lancet 1990;335:827–838.

    Article  PubMed  CAS  Google Scholar 

  16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program. JAMA 1991;265:3255–3264.

    Article  Google Scholar 

  17. Dahlöf B, Lindholm L H, Hansson L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish trial in Old Patients with Hypertension (STOPHypertension). Lancet 1991;338:1281–1285.

    Article  PubMed  Google Scholar 

  18. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Brit Med J 1992;304:405–412.

    Article  Google Scholar 

  19. Staessen J A, Fagard R, Thijs L, Celis H, Arabidze G G, Birkenhdger W H, Buipitt CJ, de Leeuw P W, Dollery C T, Fletcher A E, Forette F, Leonetti G, Nachev C, O’Brien E T, Rosenfeld J, Rodicio J L, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757–764.

    Article  PubMed  CAS  Google Scholar 

  20. Lindholm L, Ejlertsson G, Scherstein B. High risk of cerebro-cardiovascular morbidity in well treated male hypertensives. A retrospective study of 40–59-year-old hypertensives in a Swedish primary care district. Acta Med Scand 1984;216:251–259.

    Article  PubMed  CAS  Google Scholar 

  21. Isles C G, Walker L M, Beevers D G, Brown I, Cameron H L, Clarke J, Hawthorne V, Hole D, Lever A F, Robertson J W K, Wapshaw J A. Mortality in patients of the Glasgow Blood Pressure Clinic. JHypertens 1986;4:141–156.

    Article  CAS  Google Scholar 

  22. Hansson L. Editorial: How far should blood pressure be lowered? What is the role of the J-curve? Am J Hypertension 1990;3:726–729. 17

    Article  CAS  Google Scholar 

  23. Stewart I McDG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979;i:861–865.

    Article  Google Scholar 

  24. Cruickshank J M, Thorp J M, Zacharias F J. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581–584.

    Article  PubMed  CAS  Google Scholar 

  25. Alderman, M H, Ooi W L, Madhavan S, Cohen H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA 1989;262:920–924.

    Article  PubMed  CAS  Google Scholar 

  26. van den Hoogen PCW, van Popele NM, Feskens EJM, van der Kuip DAM, Grobbee DE, Hofman A, Witteman JCM. Blood pressure and risk of myocardial infarction in elderly men and women: the Rotterdam Study. J Hypertens 1999;17:1373–1378.

    Article  PubMed  Google Scholar 

  27. Hansson L, Hedner T, Dahlof B. Prospective Randomized Open Blinded End-point (PROBE) Study: A novel design for intervention trials. BLOOD PRESSURE= 1992; 1: 113–119.

    Article  PubMed  CAS  Google Scholar 

  28. Hansson I, Zanchetti A et al. for the HOT Study Group. Effects of aggressive lowering of blood pressure in patients with hypertension and type 2 diabetes. The Hypertension Optimal Treatment — HOT — Study. 1999 (in preparation).

    Google Scholar 

  29. Tatti P, Guarisco R, Di Mauro P, Strollo F. Reduced risk of major cardiovascular events with the association of two antihypertensive drugs in a non-insulin dependent diabetic population. American Diabetes Association Annual Meeting. San Fransisco, June 8–11, 1996 (poster).

    Google Scholar 

  30. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo F. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). American Heart Association 70th Scientific Meeting. Orinado, November 9–12, 1997 (poster). antagonists. J Hypertens 1998;16:119–124.

    Article  Google Scholar 

  31. van Zwieten PA, Hansson L. Calcium antagonists and safety: the turning of the tide. BLOOD PRESSURE 1999;8:5–8. 18

    Article  PubMed  Google Scholar 

  32. Curd J D, Pressel S L, Cutler J A, Savage P J, Applegate W B, Black H, Camel G, Davis B R, Frost P H, Gonzalez N, Guthrie G, Oberman A, Rutan G H, Stamler J for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886–1892.

    Article  Google Scholar 

  33. Lewis E J, Hunsicker L G, Bain R P, Rohde R D, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Hypertension Research, Department of Public Health and Social Sciences, University of Uppsala, P O Box 609, S- 751 25, Uppsala, Sweden

    Lennart Hansson M.D.

Authors
  1. Lennart Hansson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Department M (Diabetes & Endocrinology), Aarhus Kommunehospital Aarhus University Hospital, Aarhus C, Denmark

    Carl Erik Mogensen

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hansson, L. (2000). Update of the Latest Intervention Trials in Hypertension and Type 2 Diabetes. In: Mogensen, C.E. (eds) The Kidney and Hypertension in Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4499-9_45

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4499-9_45

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7028-4

  • Online ISBN: 978-1-4615-4499-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation